Shenzhen-based Biosysen and Zhejiang-based FlectoThink sign cooperation agreements with Anting town in Shanghai's Jiading district. [Photo/WeChat ID: sh-jiading]
Shenzhen-based Biosysen and Zhejiang-based FlectoThink, two leading medical companies focusing on synthetic biology and brain-machine interfaces, respectively, signed cooperation agreements with Anting town, located in Shanghai's Jiading district, during an exchange event for medical technology innovation enterprises held in Shenzhen on March 20.
The two companies, Biosysen and FlectoThink, are partners of PwC. The event is a testament to the power of collaboration, as PwC and the Anting town government joined forces to harness PwC's innovative ecosystem. Together, they are exploring cooperation and win-win opportunities, paving the way for a brighter future in the medical industry.
Biosysen, a 2019 establishment, focuses on synthetic biology, particularly in food, medical testing, daily chemicals, and medical protein development. The company has secured substantial financing and boasts an advanced manufacturing platform.
FlectoThink, founded in 2020, specializes in non-invasive brain-machine interface technology, catering to applications in consumer electronics and the medical field. The company's expertise spans various scientific disciplines and has accumulated many patents.
These signings align with Anting town's strategic development. With a clear vision to become a hub for innovative medical companies, Anting town is poised for a promising future. With the support of PwC, the town is set to foster collaborations with more high-quality enterprises in the medical and health industry, creating a thriving ecosystem of innovation and growth.
A rendering of Anting International Medical Industrial Park. [Photo/WeChat ID: sh-jiading]